Daily market recaps with key events, stock movements, and global influences 5 posts • GPT (4.1 mini) Published May 30, 2025, 03:30 PM Genentech, a subsidiary of Roche, has reported promising long-term results for its experimental BTK inhibitor, fenebrutinib, in the treatment of relapsing multiple sclerosis (MS). Phase 2 data indicate that fenebrutinib maintains near-complete suppression of disease activity and prevents disability progression for up to 96 weeks, or nearly two years.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Johnson's Imaavy
Intellia Shares Fall 25% After Grade 4 Liver Event in MAGNITUDE Trial for ATTR-CM Gene Therapy
Daily market recaps with key events, stock movements, and global influences 11 posts • GPT (4.1) Updated May 29, 2025, 04:39 PM Intellia Therapeutics disclosed in a regulatory filing that a participant in its ongoing Phase 3 MAGNITUDE trial for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) experienced a grade 4 elevation in liver enzymes (ALT and AST), indicating severe liver stress.
Biohaven Unveils BHV-1400 for IgA Nephropathy and BHV-1300 for Graves' Disease with Positive ADC and TRAP Degrader Data
Daily market recaps with key events, stock movements, and global influences 4 posts • GPT (4.1 mini) Updated May 28, 2025, 07:46 PM Biohaven Ltd. presented updates on its oncology and degrader platforms during its recent R&D Day event. The company showcased preliminary clinical data on innovative Trop2 and FGFR3 antibody drug conjugates (ADCs) incorporating a novel TopoIx payload, which have the potential to treat a wide variety of tumors.
FDA Halts Rocket Pharma Danon Gene Therapy Trial After Patient Death, Shares Drop Over 60%
Daily market recaps with key events, stock movements, and global influences 31 posts • GPT (4.1) Updated May 28, 2025, 03:08 AM Rocket Pharmaceuticals announced that a patient participating in its Phase 2 pivotal trial of RP-A501, an investigational gene therapy for Danon disease, has died following serious complications.
FDA Halts Rocket Pharma Danon Gene Therapy Trial After Patient Death; Shares Drop 63% on May 23
22 posts • GPT (4.1) Updated May 27, 2025, 04:24 PM The U.S. Food and Drug Administration (FDA) has placed a clinical hold on Rocket Pharmaceuticals' Phase 2 gene therapy trial of RP-A501 for Danon disease following the death of a patient. The patient experienced capillary leak syndrome after receiving a high-dose AAV9 vector (6.7×10¹³ GC/kg) and a novel immune suppression agent, identified as a C3 inhibitor.
Biogen and City Therapeutics Ink $46M RNAi Deal Worth Over $1B; BrainStorm Partners with Minaris for NurOwn® ALS Trials
5 posts • GPT (4.1 mini) Published May 27, 2025, 12:15 PM BrainStorm Cell Therapeutics has secured a key manufacturing partnership with Minaris to support its upcoming NurOwn® Phase 3b clinical trials for amyotrophic lateral sclerosis (ALS). In a separate development, Biogen and City Therapeutics announced a strategic research collaboration to develop select novel RNA interference (RNAi)-based therapies, leveraging City Therapeutics' next-generation RNAi engineering technologies.
Rocket Pharmaceuticals Pauses Phase 2 RP-A501 Trial for Danon Disease After FDA Clinical Hold Following Patient Death
6 posts • GPT (4.1 mini) Published May 27, 2025, 11:18 AM Rocket Pharmaceuticals announced a clinical hold on its Phase 2 pivotal trial of RP-A501, a gene therapy candidate for Danon disease, following the death of a patient. The patient experienced a serious adverse event related to capillary leak syndrome and subsequently passed away due to an acute systemic infection. The U.S. Food and Drug Administration (FDA) imposed the clinical hold to allow for further evaluation of the trial's safety.
ALS Drug Ulefnersen (Jacifusen) Enables Recovery in FUS-ALS: 12-Patient Case Series Shows 83% Biomarker Drop
Daily market recaps with key events, stock movements, and global influences 13 posts • GPT (4.1) Published May 26, 2025, 01:08 AM An experimental therapy called ulefnersen, also known as jacifusen, has produced notable clinical improvements in patients with a rare, aggressive form of amyotrophic lateral sclerosis (ALS) caused by FUS gene mutations, according to a case series of 12 patients published in The Lancet and led by Columbia University neurologist Neil Shneider in collaboration with...
Brazil's SUS Administers R$7 Million Zolgensma for SMA; Spain Funds First Genetic ALS Treatment; New MS Drug Trial
Daily market recaps with key events, stock movements, and global influences MOST EXPENSIVE MEDICINE IN THE WORLD | SUS performs the third infusion of zolgensma in a baby with SMA in São Paulo. With the procedure performed at the Unicamp Hospital, SUS expands access to the world's most expensive gene therapy, which costs around R$ 7 million per dose.
FDA Approves Genentech’s Susvimo for Diabetic Retinopathy; Columvi Extends Survival in Lymphoma; EMA Endorses Longer Eylea Dosing Intervals
Daily market recaps with key events, stock movements, and global influences 6 posts • GPT (4.1 mini) Published May 24, 2025, 12:53 PM The U.S. Food and Drug Administration has approved Genentech's Susvimo for the treatment of diabetic retinopathy, marking a new option for patients with this condition.
FDA Approves GSK's Nucala Once-Monthly for COPD, Cutting Exacerbations by 21% and Competing With Sanofi's Dupixent
Daily market recaps with key events, stock movements, and global influences 10 posts • GPT (4.1) Updated May 23, 2025, 06:42 PM The U.S. Food and Drug Administration (FDA) has approved GSK's Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with chronic obstructive pulmonary disease (COPD) who have an eosinophilic phenotype and whose disease is inadequately controlled by existing inhaled therapies.
Carl June, Bruce Levine, Isabelle Rivière, Michel Sadelain Win 2025 Richard N. Merkin Prize in Biomedical Technology for CAR T-Cell Therapy
Daily market recaps with key events, stock movements, and global influences 5 posts • GPT (4.1 mini) Published May 23, 2025, 08:33 AM Carl June of the University of Pennsylvania, Bruce Levine also from Penn, Isabelle Rivière of Takeda Pharmaceuticals, and Michel Sadelain from Columbia University have been awarded the 2025 Richard N. Merkin Prize in Biomedical Technology. The award recognizes their pioneering work in developing CAR T-cell therapy for cancer treatment.
GSK’s Anti-IL-5 Biologic Nucala Approved by FDA for COPD, Targeting £500 Million Market Amid Sanofi Competition
5 posts • GPT (4.1 mini) Published May 22, 2025, 08:40 PM GlaxoSmithKline (GSK) announced that its biologic drug Nucala (mepolizumab) has received approval from the US Food and Drug Administration (FDA) as an add-on treatment for adults living with chronic obstructive pulmonary disease (COPD). This approval positions GSK to compete more aggressively with rival pharmaceutical company Sanofi in the COPD treatment market.
Zevtera (Ceftobiprole), Advanced-Generation Cephalosporin, Now Available in U.S. to Treat Three Types of Bacterial Infections
Daily market recaps with key events, stock movements, and global influences 5 posts • GPT (4.1 mini) Published May 22, 2025, 06:30 AM Zevtera (ceftobiprole), an advanced-generation cephalosporin antibiotic, has become commercially available in the United States. It is approved for the treatment of three types of bacterial infections, including Staphylococcus aureus bacteremia. Zevtera is noted for its effectiveness against both gram-positive and gram-negative bacteria.
CEL-SCI (CVM) Seeks Saudi Approval for Cancer Drug Multikine, Plans Stock Combination, Commercialization by Summer 2025
Daily market recaps with key events, stock movements, and global influences 4 posts • GPT (4.1 mini) Published May 21, 2025, 02:18 PM CEL-SCI Corporation has announced a combination of its common stock. The company is also seeking regulatory approval from the Saudi Food and Drug Authority (SFDA) for its investigational cancer medicine, Multikine. If approved, Multikine could potentially be available for commercialization in Saudi Arabia by the summer of 2025. The stock ticker for CEL-SCI is CVM.
EMA Recommends Brentuximab Vedotin Plus ECADD for Hodgkin Lymphoma; Japan Approves GSK’s Blenrep for Relapsed/Refractory Multiple Myeloma
4 posts • GPT (4.1 mini) Published May 20, 2025, 05:04 AM The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of brentuximab vedotin combined with ECADD for the treatment of newly diagnosed stage IIB to IV Hodgkin lymphoma. Meanwhile, the Japan Ministry of Health, Labour and Welfare (MHLW) has approved GSK's Blenrep (belantamab mafodotin)-based combination therapies for relapsed or refractory multiple myeloma.
Boehringer Ingelheim Reports Positive Phase 3 Results for Oral PDE4 Inhibitor Nerandomilast in IPF With FVC Preservation, US Approval Expected in 2025 | DeepNewz Health
Daily market recaps with key events, stock movements, and global influences 5 posts • GPT (4.1 mini) Published May 20, 2025, 01:07 AM Boehringer Ingelheim announced positive Phase 3 results for nerandomilast, an oral PDE4 inhibitor for idiopathic pulmonary fibrosis (IPF), showing statistically significant preservation of forced vital capacity (FVC) and a clean safety profile.
AMVUTTRA Shows Benefits in HELIOS-B; Intellia Nex-z Phase 1 Data and Piper NKTR REZOLVE-AD June 2025 Update at ASGCT
6 posts • GPT (4.1 mini) Published May 19, 2025, 04:50 AM Recent data from the HELIOS-B trial indicate that AMVUTTRA® (vutrisiran) significantly reduces mortality and various cardiovascular events in patients with ATTR amyloidosis with cardiomyopathy, highlighting its therapeutic potential.
Brazil’s SUS Starts Free Zolgensma Gene Therapy for 137 Children with AME; Applications in Recife and Brasília; Anvisa Approves Friedreich’s Ataxia Drug | DeepNewz Brazil
Daily market recaps with key events, stock movements, and global influences 10 posts • GPT (4.1 mini) Published May 18, 2025, 12:22 AM The Brazilian public health system (SUS) has begun administering Zolgensma, a gene therapy treatment for spinal muscular atrophy (AME) type 1, marking a historic milestone as the first gene therapy incorporated into SUS.
Daily market recaps with key events, stock movements, and global influences 4 posts • GPT (4.1 mini) Published May 17, 2025, 04:15 PM The U.S. Food and Drug Administration has approved a self-administered migraine drug developed by Amneal Pharmaceuticals, providing patients with a faster and more convenient treatment option. Chronic migraine, a neurological disease causing frequent and severe headaches, affects approximately 80 million people worldwide.
Rocket Pharmaceuticals Shows PKP2 Protein Increase with RP-A601 in PKP2-ACM at ASGCT; Analysts Raise Price Targets
6 posts • GPT (4.1 mini) Published May 16, 2025, 08:16 PM At the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in May 2025, several biotechnology companies presented advancements in gene therapy and vector technology. Latus Bio unveiled a new AAV-Ep+ capsid variant capable of unprecedented protein production in the brain.
FDA Approves Merck’s WELIREG for PPGL, AbbVie Lung Cancer Drug, Amneal Migraine Therapy; Retifanlimab, Durvalumab, Travere sNDA; Amgen Fined $271M | DeepNewz Law
Daily market recaps with key events, stock movements, and global influences 13 posts • GPT (4.1 mini) Published May 16, 2025, 01:38 AM The U.S. Food and Drug Administration (FDA) has recently approved several new drugs across various therapeutic areas. Merck's WELIREG® (belzutifan) received FDA approval for treating adults and pediatric patients aged 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL).
FDA Grants Orphan Drug Designations for Thermosome’s Soft Tissue Sarcoma Therapy, CNS Pharmaceuticals’ TPI 287, and Cure Rare Disease’s SCA3 Treatment | DeepNewz Health
Daily market recaps with key events, stock movements, and global influences 5 posts • GPT (4.1 mini) Published May 15, 2025, 03:06 AM Several biopharmaceutical companies have recently secured Orphan Drug Designations from the U.S. Food and Drug Administration (FDA) for therapies targeting rare diseases. Thermosome obtained the designation for its soft tissue sarcoma therapy.
Ubrogepant Alleviates Neck Stiffness, Fatigue and Headaches in Paradigm Shift for Migraine Prodromal Symptoms
Daily market recaps with key events, stock movements, and global influences 5 posts • GPT (4.1 mini) Updated May 15, 2025, 03:05 AM A new drug called ubrogepant has been shown to alleviate not only the headache phase of migraines but also the early symptoms that precede the pain, such as neck stiffness and fatigue. This represents a paradigm shift in migraine treatment, as it is the first medication to address the prodromal symptoms before the onset of headache.
Biohaven’s Troriluzole NDA for Spinocerebellar Ataxia Faces Q3 2025 FDA PDUFA Extension; J&J Reports Stable FDA Operations
Daily market recaps with key events, stock movements, and global influences 5 posts • GPT (4.1 mini) Published May 15, 2025, 03:06 AM Biohaven Pharmaceuticals Inc.'s near-term stock focus remains on the FDA's action regarding its drug Troriluzole for Spinocerebellar Ataxia (SCA). The company completed a mid-cycle review and reiterated a third-quarter 2025 Prescription Drug User Fee Act (PDUFA) timeline.
10 posts • GPT (4.1 mini) Published May 14, 2025, 08:00 PM The 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) took place in New Orleans, showcasing advancements in gene and cell therapies. Key presentations included Affinia Therapeutics' new data on its lead AFTX-201 program targeting BAG3 Dilated Cardiomyopathy, as well as breakthroughs in blood-brain barrier (BBB) penetrating adeno-associated virus (AAV) capsids and proprietary manufacturing technologies.
Invivyd in Waltham Launches Measles Antibody Program as U.S. Cases Exceed 1,000; HHS Kennedy Leads Efforts
4 posts • GPT (4.1 mini) Published May 14, 2025, 10:59 AM Invivyd, a Waltham, Massachusetts-based biotech company formerly known as Adagio Therapeutics, has announced a new drug discovery program focused on developing a monoclonal antibody treatment for measles. This initiative comes amid a rise in measles cases in the United States, which recently surpassed 1,000 cases within the first five months of 2025, marking the first time in five years that this threshold has been exceeded.
HCW Biologics Reports Positive CAR-T Results for HCW9206 Against HIV-1, CD19+ Leukemia; Stock Surges Over 240%, $5M Offering
Daily market recaps with key events, stock movements, and global influences 6 posts • GPT (4.1 mini) Published May 14, 2025, 02:47 AM HCW Biologics (NASDAQ: HCWB) reported positive preclinical results for its proprietary compound HCW9206, a fusion protein that demonstrated superior performance in CAR-T manufacturing.
Gene Therapy Developed by CIEMAT and Rocket Pharmaceuticals Restores Immunity in Nine Children With LAD-I
12 posts • GPT (4.1) Published May 11, 2025, 03:21 PM A multinational clinical trial has shown that gene therapy can restore immune function and eliminate life-threatening infections in children with severe leukocyte adhesion deficiency type I (LAD-I), an extremely rare genetic disorder affecting about one in a million people worldwide.
Hospital La Paz Successfully Treats 11-Year-Old Girl’s Rare Autoimmune Disease with CAR-T Therapy in Madrid
Daily market recaps with key events, stock movements, and global influences 13 posts • GPT (4.1 mini) Published May 7, 2025, 04:20 AM The Hospital La Paz in Madrid has successfully treated an 11-year-old girl suffering from a rare autoimmune disease using CAR-T therapy, marking a first in medical history for this type of treatment. CAR-T therapy, previously used primarily against leukemia, has been adapted here to address an autoimmune condition with positive outcomes.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Johnson's
Contact Johnson's, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack